Cambrex Licenses Cell Line to Chugai Pharmaceutical Co.
Under the terms of the renewable license agreement, Chugai Pharmaceutical Company will use one of the conditionally immortalized cell lines for a period of one year in their pharmaceutical drug discovery program. The license agreement has been lead by Cambrex's exclusive distributor in Japan, GeneFrontier Corporation. Further financial details of the agreement are not disclosed.
The licensed cell lines were created using a clone of a specially modified large T antigen and licensed telomerase technology. Cambrex continues to invest in several programs to conditionally immortalize different cell types critical to understand and manage metabolic disease.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.